The DOI matches its Crossref record; 247 of the 247 references it cites were found in a registry or an index.
Nuclear receptors and nonalcoholic fatty liver disease
Open accessAbstract
Nuclear receptors are transcription factors which sense changing environmental or hormonal signals and effect transcriptional changes to regulate core life functions including growth, development, and reproduction. To support this function, following ligand-activation by xenobiotics, members of subfamily 1 nuclear receptors (NR1s) may heterodimerize with the retinoid X receptor (RXR) to regulate transcription of genes involved in energy and xenobiotic metabolism and inflammation. Several of these receptors including the peroxisome proliferator-activated receptors (PPARs), the pregnane and xenobiotic receptor (PXR), the constitutive androstane receptor (CAR), the liver X receptor (LXR) and the farnesoid X receptor (FXR) are key regulators of the gut:liver:adipose axis and serve to coordinate metabolic responses across organ systems between the fed and fasting states. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and may progress to cirrhosis and even hepatocellular carcinoma. NAFLD is associated with inappropriate nuclear receptor function and perturbations along the gut:liver:adipose axis including obesity, increased intestinal permeability with systemic inflammation, abnormal hepatic lipid metabolism, and insulin resistance. Environmental chemicals may compound the problem by directly interacting with nuclear receptors leading to metabolic confusion and the inability to differentiate fed from fasting conditions. This review focuses on the impact of nuclear receptors in the pathogenesis and treatment of NAFLD. Clinical trials including PIVENS and FLINT demonstrate that nuclear receptor targeted therapies may lead to the paradoxical dissociation of steatosis, inflammation, fibrosis, insulin resistance, dyslipidemia and obesity. Novel strategies currently under development (including tissue-specific ligands and dual receptor agonists) may be required to separate the beneficial effects of nuclear receptor activation from unwanted metabolic side effects. The impact of nuclear receptor crosstalk in NAFLD is likely to be profound, but requires further elucidation. This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., Qiu, Z., Maher, L., Redinbo, M. R., Phillips, R. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.014 · Cited by 1,066
Wu, Z., Rosen, E. D., Brun, R., Hauser, S., Adelmant, G., Troy, A. E., McKeon, C., Darlington, G. J., & Spiegelman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80306-8 · Cited by 1,015
Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Kliewer, S. A., Goodwin, B., & Willson, T. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0038 · Cited by 921
Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P. T., Lawlor, D. A., & Fraser, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140908 · Cited by 898
Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation
Reddy, J. K., & Sambasiva Rao, M. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00521.2005 · Cited by 860
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity
Watkins, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., Williams, S. P., Willson, T. M., Kliewer, S. A., & Redinbo, M. R. (2001) · Science · doi:10.1126/science.1060762 · Cited by 760
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“For example, the activation of NFκB, leading to nuclear translocation and subsequent DNA binding of this inflammatory transcription factor, is blunted by the action of PPARα [31,54,55].”
BackgroundIntestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids
Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., & Lazar, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23975 · Cited by 711
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705
Honkakoski, P., Zelko, I., Sueyoshi, T., & Negishi, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5652 · Cited by 700
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Humanized xenobiotic response in mice expressing nuclear receptor SXR
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., & Evans, R. M. (2000) · Nature · doi:10.1038/35019116 · Cited by 660
Maglich, J. M., Stoltz, C. M., Goodwin, B., Hawkins-Brown, D., Moore, J. T., & Kliewer, S. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.638 · Cited by 654
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646
A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622
Yu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., Rao, M. S., Gonzalez, F. J., & Reddy, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210062200 · Cited by 619
Hepatic Fatty Acid Transporter Cd36 Is a Common Target of LXR, PXR, and PPARγ in Promoting Steatosis
Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J. H., Khadem, S., Ren, S., Li, S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.037 · Cited by 605
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Fu, L., John, L. M., Adams, S. H., Yu, X. X., Tomlinson, E., Renz, M., Williams, P. M., Soriano, R., Corpuz, R., Moffat, B., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1671 · Cited by 579
Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576
REV-ERB and ROR nuclear receptors as drug targets
Kojetin, D. J., & Burris, T. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4100 · Cited by 576
A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
Urizar, N. L., Liverman, A. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002) · Science · doi:10.1126/science.1072891 · Cited by 549
Gachon, F., Olela, F. F., Schaad, O., Descombes, P., & Schibler, U. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.015 · Cited by 512
Willson, T. M., & Kliewer, S. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd753 · Cited by 503
Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488
Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 487
Gervois, P., Fruchart, J.-C., Delerive, P., & Staels, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004045200 · Cited by 456
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448
Cipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 416
Peroxisome Proliferator Activated Receptor-α Expression in Human Liver
Palmer, C. N. A., Hsu, M.-H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.14 · Cited by 416
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Zhou, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26283 · Cited by 402
Induction of bilirubin clearance by the constitutive androstane receptor (CAR)
Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., & Moore, D. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630614100 · Cited by 390
Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR
Tolson, A. H., & Wang, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.006 · Cited by 386
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
FXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 381
Zhu, Y., Alvares, K., Huang, Q., Rao, M. S., & Reddy, J. K. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74184-2 · Cited by 374
Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance
James, O. F. W., & Day, C. P. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80073-1 · Cited by 373
Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., Ren, S., Evans, R. M., & Xie, W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511116200 · Cited by 368
Yamagata, K., Daitoku, H., Shimamoto, Y., Matsuzaki, H., Hirota, K., Ishida, J., & Fukamizu, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314322200 · Cited by 364
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors
Sueyoshi, T., & Negishi, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.123 · Cited by 362
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl249 · Cited by 357
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027466 · Cited by 352
Patsouris, D., Reddy, J. K., Müller, M., & Kersten, S. (2006) · Endocrinology · doi:10.1210/en.2005-1132 · Cited by 340
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
Ferslew, B. C., Xie, G., Johnston, C. K., Su, M., Stewart, P. W., Jia, W., Brouwer, K. L. R., & Sidney Barritt, A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3776-8 · Cited by 335
Kodama, S., Koike, C., Negishi, M., & Yamamoto, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.7931-7940.2004 · Cited by 334
Zhu, X., Owen, J. S., Wilson, M. D., Li, H., Griffiths, G. L., Thomas, M. J., Hiltbold, E. M., Fessler, M. B., & Parks, J. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006486 · Cited by 331
Oxysterol biosynthetic enzymes
Russell, D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00142-6 · Cited by 319
Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., Montana, V. G., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00207-5 · Cited by 312
FGF-19, A NOVEL FIBROBLAST GROWTH FACTOR WITH UNIQUE SPECIFICITY FOR FGFR4
Xie, M.-H., Holcomb, I., Deuel, B., Dowd, P., Huang, A., Vagts, A., Foster, J., Liang, J., Brush, J., Gu, Q., et al. (1999) · Cytokine · doi:10.1006/cyto.1999.0485 · Cited by 301
Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00003 · Cited by 292
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Regulation of Carbohydrate Metabolism by the Farnesoid X Receptor
Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J., Cook, T., Christe, M. E., Michael, L. F., & Burris, T. P. (2005) · Endocrinology · doi:10.1210/en.2004-0965 · Cited by 288
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14505 · Cited by 286
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Ito, A., Hong, C., Rong, X., Zhu, X., Tarling, E. J., Hedde, P. N., Gratton, E., Parks, J., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.08009 · Cited by 281
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214505 · Cited by 279
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
Gonzalez, F. J., & Shah, Y. M. (2008) · Toxicology · doi:10.1016/j.tox.2007.09.030 · Cited by 262
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease
Dong, B., Saha, P. K., Huang, W., Chen, W., Abu-Elheiga, L. A., Wakil, S. J., Stevens, R. D., Ilkayeva, O., Newgard, C. B., Chan, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909731106 · Cited by 260
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
Shah, Y. M., Morimura, K., Yang, Q., Tanabe, T., Takagi, M., & Gonzalez, F. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00317-07 · Cited by 255
Watanabe, M., Horai, Y., Houten, S. M., Morimoto, K., Sugizaki, T., Arita, E., Mataki, C., Sato, H., Tanigawara, Y., Schoonjans, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248203 · Cited by 254
Saini, S. P. S., Sonoda, J., Xu, L., Toma, D., Uppal, H., Mu, Y., Ren, S., Moore, D. D., Evans, R. M., & Xie, W. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.2.292 · Cited by 251
T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR
Mitro, N., Vargas, L., Romeo, R., Koder, A., & Saez, E. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.03.047 · Cited by 250
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Lutchman, G., Modi, A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T. J., Premkumar, A., et al. (2007) · Hepatology · doi:10.1002/hep.21661 · Cited by 244
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed · doi:10.3748/wjg.v17.i23.2801 · Cited by 242
PXR and CAR in energy metabolism
Wada, T., Gao, J., & Xie, W. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.03.003 · Cited by 242
Corton, J. C., Cunningham, M. L., Hummer, B. T., Lau, C., Meek, B., Peters, J. M., Popp, J. A., Rhomberg, L., Seed, J., & Klaunig, J. E. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.835784 · Cited by 238
The Biological Actions of Dehydroepiandrosterone Involves Multiple Receptors
Webb, S. J., Geoghegan, T. E., Prough, R. A., & Michael Miller, K. K. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569877 · Cited by 237
Self-citationIII. Peroxisomal β-oxidation, PPARα, and steatohepatitis
Reddy, J. K. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.6.g1333 · Cited by 236
Gao, J., He, J., Zhai, Y., Wada, T., & Xie, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016808 · Cited by 233
Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233
Bhalla, S., Ozalp, C., Fang, S., Xiang, L., & Kemper, J. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405423200 · Cited by 230
Yang, Z.-X., Shen, W., & Sun, H. (2010) · Hepatology International · doi:10.1007/s12072-010-9202-6 · Cited by 226
Cerveny, L., Svecova, L., Anzenbacherova, E., Vrzal, R., Staud, F., Dvorak, Z., Ulrichova, J., Anzenbacher, P., & Pavek, P. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014456 · Cited by 225
GILL, S., CHOW, R., & BROWN, A. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.04.002 · Cited by 222
Characterization of the Human ABCG1 Gene
Kennedy, M. A., Venkateswaran, A., Tarr, P. T., Xenarios, I., Kudoh, J., Shimizu, N., & Edwards, P. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105863200 · Cited by 217
Goto, T., Lee, J.-Y., Teraminami, A., Kim, Y.-I., Hirai, S., Uemura, T., Inoue, H., Takahashi, N., & Kawada, T. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011320 · Cited by 217
LAMBA, V (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.12.027 · Cited by 216
Toxicant-associated Steatohepatitis
Wahlang, B., Beier, J. I., Clair, H. B., Bellis-Jones, H. J., Falkner, K. C., McClain, C. J., & Cave, M. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623312468517 · Cited by 216
Self-citationCariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Zhang, Y., Breevoort, S. R., Angdisen, J., Fu, M., Schmidt, D. R., Holmstrom, S. R., Kliewer, S. A., Mangelsdorf, D. J., & Schulman, I. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59817 · Cited by 213
Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400346200 · Cited by 212
Kong, B., Luyendyk, J. P., Tawfik, O., & Guo, G. L. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144600 · Cited by 210
Nakamura, K., Moore, R., Negishi, M., & Sueyoshi, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610072200 · Cited by 203
Mutoh, S., Sobhany, M., Moore, R., Perera, L., Pedersen, L., Sueyoshi, T., & Negishi, M. (2013) · Science Signaling · doi:10.1126/scisignal.2003705 · Cited by 197
Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R., & Negishi, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1069 · Cited by 190
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lindley, C., Yan, B., Negishi, M., & LeCluyse, E. L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.348 · Cited by 179
Venteclef, N., Jakobsson, T., Ehrlund, A., Damdimopoulos, A., Mikkonen, L., Ellis, E., Nilsson, L.-M., Parini, P., Jänne, O. A., Gustafsson, J.-Å., et al. (2010) · Genes & Development · doi:10.1101/gad.545110 · Cited by 178
Minireview: PPARγ as the target of obesogens
Janesick, A., & Blumberg, B. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.01.005 · Cited by 174
Tissue-specific mRNA Expression Profiles of Human Nuclear Receptor Subfamilies
Nishimura, M., Naito, S., & Yokoi, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.135 · Cited by 173
Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Zordoky, B., & El-Kadi, A. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522151 · Cited by 169
Adiponectin, a key adipokine in obesity related liver diseases
Christa, Buechler, Josef, Wanninger, Markus, M. L., & Neumeier (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 167
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Ma, Y., Huang, Y., Yan, L., Gao, M., & Liu, D. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0986-7 · Cited by 165
LXRβ Is Required for Adipocyte Growth, Glucose Homeostasis, and β Cell Function
Gerin, I., Dolinsky, V. W., Shackman, J. G., Kennedy, R. T., Chiang, S.-H., Burant, C. F., Steffensen, K. R., Gustafsson, J.-Å., & MacDougald, O. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412564200 · Cited by 165
Honkakoski, P., Moore, R., Washburn, K. A., & Negishi, M. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.4.597 · Cited by 162
Cyphert, H. A., Ge, X., Kohan, A. B., Salati, L. M., Zhang, Y., & Hillgartner, F. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375907 · Cited by 161
Kawaguchi, K., Sakaida, I., Tsuchiya, M., Omori, K., Takami, T., & Okita, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.038 · Cited by 160
NER, a new member of the gene family encoding the human steroid hormone nuclear receptor
SHINAR, D. M., Endo, N., Rutledge, S. J., Vogel, R., Rodan, G. A., & Schmidt, A. (1994) · Gene · doi:10.1016/0378-1119(94)90080-9 · Cited by 159
Liver X Receptors Interact with Corepressors to Regulate Gene Expression
Hu, X., Li, S., Wu, J., Xia, C., & Lala, D. S. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0399 · Cited by 159
Hernandez, J., Mota, L., & Baldwin, W. (2009) · Current Pharmacogenomics and Personalized Medicine · doi:10.2174/187569209788654005 · Cited by 158
FXR and PXR: Potential therapeutic targets in cholestasis
Jonker, J. W., Liddle, C., & Downes, M. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.06.012 · Cited by 158
Ding, X., Lichti-Kaiser, K., Kim, I., Gonzalez, F. J., & Staudinger, J. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600931200 · Cited by 154
Wolfe, A. R., Thomas, A., Edwards, G., Jaseja, R., Guo, G. L., & Apte, U. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179390 · Cited by 152
PXR Ablation Alleviates Diet-Induced and Genetic Obesity and Insulin Resistance in Mice
He, J., Gao, J., Xu, M., Ren, S., Stefanović-Račić, M., O'Doherty, R. M., & Xie, W. (2013) · Diabetes · doi:10.2337/db12-1039 · Cited by 151
Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., & Miwa, M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007161 · Cited by 151
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2007) · PPAR Research · doi:10.1155/2008/132960 · Cited by 150
Roth, A. B., Looser, R., Kaufmann, M., Blättler, S. M., Rencurel, F., Huang, W., Moore, D. D., & Meyer, U. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041012 · Cited by 149
Hardwick, R. N., Fisher, C. D., Canet, M. J., Scheffer, G. L., & Cherrington, N. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041012 · Cited by 148
Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L. G., Perera, L., Rebolloso, Y. D., Sueyoshi, T., & Negishi, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.048108 · Cited by 139
Fernández-Álvarez, A. J., Álvarez, M. S., González, R., Cucarella, C., Muntané, J., & Casado, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209973 · Cited by 137
A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis
Griffett, K., Solt, L. A., Elgendy, B., Kamenecka, T. M., & Burris, T. P. (2012) · ACS Chemical Biology · doi:10.1021/cb300541g · Cited by 130
Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis
van der Meer, D. L. M., Degenhardt, T., Vaïsänen, S., de Groot, P. J., Heinäniemi, M., de Vries, S. C., Müller, M. M., Carlberg, C., & Kersten, S. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq012 · Cited by 130
Ahn, S. B., Jang, K., Jun, D. W., Lee, B. H., & Shin, K. J. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3289-x · Cited by 128
Lee, J. W., Bajwa, P. J., Carson, M. J., Jeske, D. R., Cong, Y., Elson, C. O., Lytle, C. Y., & Straus, D. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.113 · Cited by 127
Falkner, K. C., Pinaire, J. A., Xiao, G., Geoghegan, T. E., & Prough, R. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12625-9 · Cited by 127
Self-citationNarala, V. R., Adapala, R. K., Suresh, M. V., Brock, T. G., Peters-Golden, M., & Reddy, R. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085118 · Cited by 126
Alternatively spliced isoforms of the human constitutive androstane receptor
Auerbach, S. S., Ramsden, R., Stoner, M. A., Verlinde, C., Hassett, C., & Omiecinski, C. J. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg419 · Cited by 126
Tanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B. W., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 123
Wyde, M. E., Bartolucci, E., Ueda, A., Zhang, H., Yan, B., Negishi, M., & Li, Y. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.474 · Cited by 123
Mellor, C. L., Steinmetz, F. P., & Cronin, M. (2015) · Critical Reviews in Toxicology · doi:10.3109/10408444.2015.1089471 · Cited by 122
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR
Krasowski, M. D., Ni, A., Hagey, L. R., & Ekins, S. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.06.016 · Cited by 121
Maglich, J. M., Lobe, D. C., & Moore, J. T. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800226-jlr200 · Cited by 120
Alterations in intestinal fatty acid metabolism in inflammatory bowel disease
Heimerl, S., Moehle, C., Zahn, A., Boettcher, A., Stremmel, W., Langmann, T., & Schmitz, G. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.12.006 · Cited by 117
Role of farnesoid X receptor and bile acids in alcoholic liver disease
Manley, S., & Ding, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.12.011 · Cited by 116
DNA Binding-Independent Induction of I B Gene Transcription by PPAR
Delerive, P., Bosscher, K. D., Berghe, W. V., Fruchart, J., Haegeman, G., & Staels, B. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.5.0826 · Cited by 116
Structure of the Murine Constitutive Androstane Receptor Complexed to Androstenol
Li, S., Vincent, J. G., Brunzelle, J. S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M. A., FORMAN, B. M., & Fernandez, E. J. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.037 · Cited by 116
Bitter, A., Rümmele, P., Klein, K., Kandel, B. A., Rieger, J. K., Nussler, A. K., Zanger, U. M., Trauner, M., Schwab, M. G., & Burk, O. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1348-x · Cited by 114
Wei, J., Sun, X., Chen, Y., Li, Y., Song, L., Zhao, Z., Xu, B., Lin, Y., & Xu, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0356 · Cited by 114
Fernø, J., Vik‐Mo, A. O., Jassim, G., Håvik, B., Berge, K., Skrede, S., Gudbrandsen, O. A., Waage, J. E. R., Lunder, N., Mørk, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1370-x · Cited by 107
Human Receptor Activation by Aroclor 1260, a Polychlorinated Biphenyl Mixture
Wahlang, B., Falkner, K. C., Clair, H. B., Al‐Eryani, L., Prough, R. A., States, J. C., Coslo, D. M., Omiecinski, C. J., & Cave, M. C. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu083 · Cited by 106
Self-citationAl-Salman, F., & Plant, N. J. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.05.016 · Cited by 105
Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice
Uppal, H., Toma, D., Saini, S. P. S., Ren, S., Jones, T. J., & Xie, W. (2005) · Hepatology · doi:10.1002/hep.20512 · Cited by 103
Pregnane X Receptor Activators Inhibit Human Hepatic Stellate Cell Transdifferentiation In Vitro
Shepherd, E. L., Tucker, S. J., Marek, C. J., Durward, E., Leel, V., Bascal, Z. A., Monaghan, T. M., Koruth, M., Collie-Duguid, E. S. R., Mann, D. A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.012 · Cited by 102
Sookoian, S. C., Castaño, G. O., Burgueño, A. L., Gianotti, T. F., Rosselli, M. S., & Pirola, C. J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328333a1dd · Cited by 101
Takeuchi, S., Matsuda, T., Kobayashi, S., Takahashi, T., & Kojima, H. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.08.011 · Cited by 100
Role of Pregnane X Receptor in Obesity and Glucose Homeostasis in Male Mice
Spruiell, K., Richardson, R. M., Cullen, J. M., Awumey, E. M., Gonzalez, F. J., & Gyamfi, M. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494575 · Cited by 99
Enomoto, N., Takei, Y., Hirose, M., Konno, A., Shibuya, T., Matsuyama, S., Suzuki, S., Ikejima, K., & Sato, N. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047217 · Cited by 99
Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
Dong, B., Lee, J.-S., Park, Y.-Y., Yang, F., Xu, G., Huang, W., Finegold, M. J., & Moore, D. D. (2015) · Nature Communications · doi:10.1038/ncomms6944 · Cited by 97
Tan, X., Xie, G., Sun, X., Li, Q., Zhong, W. H., Qiao, P. L., Sun, X., Jia, W. P., & Zhou, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061409 · Cited by 97
Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease
Andersen, V. C., Christensen, J., Ernst, A., Jacobsen, B. A., Tjønneland, A., Krarup, H. B., & Vogel, U. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i2.197 · Cited by 95
The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Griffett, K., Welch, R. D., Flaveny, C. A., Kolar, G. R., Neuschwander-Tetri, B. A., & Burris, T. P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.009 · Cited by 95
Joshi‐Barve, S., Kirpich, I., Cave, M. C., Marsano, L. S., & McClain, C. J. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.05.006 · Cited by 94
Self-citationShan, W., Nicol, C. J. B., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2007) · Hepatology · doi:10.1002/hep.21925 · Cited by 94
Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice
Peters, J. M., Aoyama, T., Burns, A., & Gonzalez, F. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00065-9 · Cited by 93
Endogenous 24(S),25-Epoxycholesterol Fine-tunes Acute Control of Cellular Cholesterol Homeostasis
Wong, J., Quinn, C. M., Gelissen, I. C., & Brown, A. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706416200 · Cited by 92
Evans, M. J., Mahaney, P. E., Borges-Marcucci, L., Lai, K., Wang, S., Krueger, J. A., Gardell, S. J., Huard, C., Martinez, R., Vlasuk, G. P., et al. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90585.2008 · Cited by 92
Arnold, K. A., Eichelbaum, M. F., & Burk, O. (2004) · Nuclear Receptor · doi:10.1186/1478-1336-2-1 · Cited by 88
Wu, H. Q., Masset-Brown, J., Tweedie, D., et al. (1989) · PubMed · Cited by 87
Yamazaki, Y., Kakizaki, S., Horiguchi, N., Sohara, N., Sato, K., Takagi, H., Mori, M., & Negishi, M. (2006) · Gut · doi:10.1136/gut.2006.093260 · Cited by 87
Shenoy, S. D., Spencer, T. A., Mercer-Haines, N. A., Alipour, M., Gargano, M. D., Runge‐Morris, M., & Kocarek, T. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.66 · Cited by 87
PPARα contributes to colonic protection in mice with DSS-induced colitis
Azuma, Y., Nishiyama, K., Matsuo, Y., Kuwamura, M., Morioka, A., Nakajima, H., & Takeuchi, T. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.07.007 · Cited by 85
Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., & Wahli, W. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-34 · Cited by 83
Regulation of gene expression by CAR: an update
Kobayashi, K., Hashimoto, M., Honkakoski, P., & Negishi, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1522-9 · Cited by 83
DeKeyser, J. G., Stagliano, M. C., Auerbach, S. S., Prabhu, K. S., Jones, A. D., & Omiecinski, C. J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053702 · Cited by 83
Li, L., Li, H., Garzel, B., Yang, H., Sueyoshi, T., Li, Q., Shu, Y., Zhang, J., Hu, B., Heyward, S. A., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097287 · Cited by 83
Zhao, Y., Zhang, K., Giesy, J. P., & Hu, J. (2015) · Scientific Reports · doi:10.1038/srep08554 · Cited by 82
Menke, J. G., MacNaul, K. L., Hayes, N. S., Baffic, J., Chao, Y., Elbrecht, A., Kelly, L. J., Lam, M., Schmidt, A., Sahoo, S. P., et al. (2002) · Endocrinology · doi:10.1210/endo.143.7.8907 · Cited by 82
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 79
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 79
Lalloyer, F., Wouters, K., Baron, M., Caron, S., Vallez, E., Vanhoutte, J., Baugé, E., Shiri‐Sverdlov, R., Hofker, M. H., Staels, B., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.220525 · Cited by 75
Frank, C., Makkonen, H., Dunlop, T. W., Heinäniemi, M., Vaïsänen, S., & Carlberg, C. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.12.003 · Cited by 74
Beilke, L. D., Aleksunes, L. M., Holland, R. D., Besselsen, D. G., Beger, R. D., Klaassen, C. D., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023317 · Cited by 73
Sidhu, J. S., & Omiecinski, C. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36871-5 · Cited by 73
Matsukuma, K. E., Bennett, M. K., Huang, J., Wang, L., Gil, G., & Osborne, T. F. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600342-jlr200 · Cited by 72
Wahlang, B., Prough, R. A., Falkner, K. C., Hardesty, J., Song, M., Clair, H. B., Clark, B. J., States, J. C., Arteel, G. E., & Cave, M. C. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv250 · Cited by 72
Self-citationMaranghi, F., Lorenzetti, S., Tassinari, R., Moracci, G., Tassinari, V., Marcoccia, D., Virgilio, A. D., Eusepi, A., Romeo, A., Magrelli, A., et al. (2010) · Reproductive Toxicology · doi:10.1016/j.reprotox.2010.03.002 · Cited by 71
Jones, S. A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_11 · Cited by 70
Luisier, R., Lempiäinen, H., Scherbichler, N., Braeuning, A., Geissler, M., Dubost, V., Müller, A., Scheer, N., Chibout, S., Hara, H., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu038 · Cited by 70
Characterization of DNA Complexes Formed by the Nuclear Receptor Constitutive Androstane Receptor
Frank, C., González, M. M., Oinonen, C., Dunlop, T. W., & Carlberg, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305186200 · Cited by 69
Huang, H., Yu, Y., Gao, Z., Zhang, Y., Li, C., Xu, X. Y., Jin, H., Yan, W., Ma, R., Zhu, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002718 · Cited by 65
Li, D., Mackowiak, B., Brayman, T. G., Mitchell, M. D., Zhang, L., Huang, S. M., & Wang, H. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.087 · Cited by 61
Biswas, A., Pasquel, D., Tyagi, R. K., & Mani, S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.048 · Cited by 61
Osabe, M., & Negishi, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.284596 · Cited by 60
Cited by
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Roth, K., Yang, Z., Agarwal, M., Liu, W., Peng, Z., Long, Z., Birbeck, J., Westrick, J., Liu, W., & Petriello, M. C. (2021) · Environment International · doi:10.1016/j.envint.2021.106843 · Cited by 307
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
Tahri-Joutey, M., Andreoletti, P., Surapureddi, S., Nasser, B., Cherkaoui-Malki, M., & Latruffe, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168969 · Cited by 253
Metadata
- Authors
- Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., & Prough, R. A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 1859
- Issue
- 9
- Pages
- 1083-1099
- ISSN
- 1874-9399 (ISSN-L)
- OpenAlex
- W2293546533
- Cited by
- 279
- References
- 247
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.